Clinical Use of Dornase Alfa Is Associated with a Slower Rate of FEV(1) Decline in Cystic Fibrosis

OBJECTIVES: Randomized controlled trials of dornase alfa have shown forced expiratory volume in 1 second (FEV(1)) to improve in patients with cystic fibrosis (CF) but have not assessed change in the rate of lung function decline. We assessed the relationship of dornase alfa use and FEV(1) decline us...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Konstan, Michael W., Wagener, Jeffrey S., Pasta, David J., Millar, Stefanie J., Jacobs, Joan R., Yegin, Ashley, Morgan, Wayne J.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4109161/
https://ncbi.nlm.nih.gov/pubmed/21438174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.21388
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky